Zentalis Pharmaceuticals (ZNTL) FCF Margin (2024)
Zentalis Pharmaceuticals' quarterly FCF Margin came in at 147.78% in Q4 2024, down 15.24% quarter-over-quarter from 128.24% in Q1 2024.
Zentalis Pharmaceuticals has reported FCF Margin for 1 years, with the latest figure at 147.78% in Q4 2024.
- For the quarter ending Q4 2024, FCF Margin changed N/A year-over-year to 147.78%; the trailing twelve-month figure through Sep 2025 stood at 498.82% (down 7439.0% YoY), and the FY2024 full-year result was 253.74%, changed N/A from the prior year.
- FCF Margin for Q4 2024 stood at 147.78%, down from 128.24% in the prior quarter.
- The five-year high for FCF Margin was 128.24% in Q1 2024, with the low at 147.78% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -147.78% |
| Mar 31, 2024 | -128.24% |